AFT Pharmaceuticals Ltd. (AU:AFP) has released an update.
AFT Pharmaceuticals has announced a collaboration with European partners to finalize the development of a novel injectable medicine targeting a significant global market. The agreement involves a Phase III clinical trial with shared costs and potential for early income through out-licensing. The medicine, which offers a single-dose advantage over existing treatments, is expected to reach the market within three years.
For further insights into AU:AFP stock, check out TipRanks’ Stock Analysis page.